Guangzhou Baiyunshan Hanfang Launches Highly Emulsifiable Injectable Egg Yolk Lecithin

Domestic Supplier Breaks International Monopoly with GMP-Compliant, Globally Certified Lipid Excipients

【Guangzhou, China】– 2026 – Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd., a leading provider of high-end pharmaceutical lipid excipients in China, today announced the launch of its highly emulsifiable injectable egg yolk lecithin, a critical raw material for advanced drug formulations. This domestically developed product addresses the core pain point of unstable supply of high-grade injectable excipients for pharmaceutical enterprises, featuring independent intellectual property rights, green manufacturing technology, and global regulatory compliance. With this launch, the company aims to further expand its global footprint in the pharmaceutical excipient market, providing reliable domestic alternatives to international brands. The product is now available for pre-order globally through official channels.

Core Technological Breakthroughs & Product Highlights

The highly emulsifiable injectable egg yolk lecithin represents a key technological breakthrough for Guangzhou Baiyunshan Hanfang, breaking the long-term international monopoly in the high-end pharmaceutical lipid excipient sector. The company has achieved a leap in localization rate from 10% to 90% for such products by leveraging its proprietary integrated green technology, combining supercritical CO₂ extraction, membrane separation, and chromatographic separation to replace traditional polluting processes.

As a critical emulsifier and solubilizer for injectable emulsions and liposome formulations, this product ensures stable performance and consistent quality, meeting the strict requirements of pharmaceutical manufacturers and research institutions for high-grade excipients. It provides a reliable domestic supply option, reducing dependence on imported materials and enhancing the security of the domestic pharmaceutical supply chain.

Global Compliance & Certifications

To meet global market access requirements, Guangzhou Baiyunshan Hanfang’s injectable egg yolk lecithin has obtained a range of international certifications, including EU CEP, US FDA US-DMF, Mexico Cofepris, and India DCGI. These certifications confirm that the product complies with regulatory standards in major markets across Europe, North America, and Asia-Pacific, enabling its wide application in global pharmaceutical production.

Supply Information & Customized Services

The highly emulsifiable injectable egg yolk lecithin is now open for pre-order globally through the company’s official website and authorized distributors. The company offers a composite business model including direct sales, agency distribution, custom processing, and technical services, allowing it to provide tailored solutions for different client needs, from pharmaceutical manufacturers to research institutions.

Authoritative Quotes

"The launch of our highly emulsifiable injectable egg yolk lecithin marks a significant step in our global development strategy, addressing the long-standing supply gap in the domestic high-end pharmaceutical excipient market," said Xu Wendong, General Manager of Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. and Deputy Director of the National Engineering Research Center. "This achievement reflects our commitment to technological self-reliance, breaking 'bottleneck' technologies, and ensuring the security of the pharmaceutical industry chain."

Industry Background & Corporate Strategy

Against the backdrop of growing global demand for reliable pharmaceutical excipients, Guangzhou Baiyunshan Hanfang’s focus on domestic innovation aligns with the industry trend of enhancing supply chain resilience. The company’s breakthrough not only supports domestic pharmaceutical enterprises but also positions it as a competitive player in the global market, providing high-quality alternatives to international suppliers.

Future Plans & Next Steps

Looking ahead, Guangzhou Baiyunshan Hanfang will continue to deepen its research and development in high-end pharmaceutical lipid excipients, increasing investment in green manufacturing technologies and expanding its product portfolio. The company also plans to further improve its global sales and service network, providing localized support for clients in more countries and regions.

Company Profile

Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. was founded in 1998 as a wholly state-owned subsidiary of Guangzhou Pharmaceutical Holdings (GPH), a Fortune Global 500 enterprise. It is a national-level specialized, sophisticated, unique, and new "Little Giant" enterprise, hosting the National Engineering Research Center for Chinese Medicine Pharmaceutical Process Technology and New Drug Creation, the only national-level engineering research center in the pharmaceutical lipid sector. The company serves over 1,000 clients worldwide, including global pharmaceutical giants like B. Braun Company and AstraZeneca, with products sold in more than 20 countries and regions. Its mission is to achieve technological self-reliance, solve "bottleneck" problems, and safeguard human health.

For more information, please visit the official website: http://byshanhanfang.com/.

Contact Information

Company: Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.
Official Website: http://byshanhanfang.com/

© 2026 Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. All rights reserved. This news release may not be reproduced in whole or in part without prior written permission.